Showing results (51-60 of 186) with videos related to

Sort By:
Pageof 19
Cancer Reports (Hoboken, N.J.)|February 18, 2026
High-Dose Continuous Infusion Ifosfamide as Effective Palliation in a Patient With Relapsed Ewing Sarcoma With Bone Marrow Infiltration and Severe Thrombocytopenia: A Case ReportFabio Murtas, Benedetta Chiusole, Ilaria Tortorelli, et al.
American Journal of Hematology|June 25, 2010
ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patientsRoberta Zanotti, Franzesco Frattini, Paolo Ghia, et al.
Critical Reviews in Oncology/Hematology|June 4, 2021
Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysisCarlo Visco, Francesca Pregnolato, Isacco Ferrarini, et al.
British Journal of Haematology|February 4, 2020
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapyRory McCulloch, Carlo Visco, Toby A Eyre, et al.
Cancers|December 11, 2019
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid LeukemiaPaul Takam Kamga, Giada Dal Collo, Federica Resci, et al.
Cytotherapy|July 8, 2020
A serum-free protocol for the ex vivo expansion of Cytokine-Induced Killer cells using gas-permeable static culture flasksPierangela Palmerini, Anna Dalla Pietà, Roberta Sommaggio, et al.
British Journal of Haematology|May 16, 2020
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphomaFulvio Massaro, Yana Stepanishyna, Martina Manni, et al.
Cancers|January 20, 2021
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell TherapyMiriam Marangon, Carlo Visco, Anna Maria Barbui, et al.
Cytotherapy|September 10, 2025
Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensusStefano Luminari, Annalisa Chiappella, Alice Di Rocco, et al.
Haematologica|September 22, 2011
Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomesEnrica Rampazzo, Laura Bonaldi, Livio Trentin, et al.
Pageof 19